Clinical Trial Update: Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon Like Peptide 2 [Phase 3]

View source ↗

Summary

Phase 3 clinical trial examining how glucagon-like peptide-2 regulates intestinal and hepatic lipoprotein production has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia

Drugs mentioned

• Glucagon-like peptide-2 (glucagon-like peptide-2)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Dyslipidemia | Phase 3 | Status: COMPLETED